ArticleComputational and structural biotechnology journal2025
Identifying the risk of Kawasaki disease based solely on routine blood test features through novel construction of machine learning models.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Generalizable deep-learning-based mRNA-protein interaction prediction strongly depends on protein diversity.Journal of cheminformatics · 2026Article
- Polymorphism-driven immune disruptions in Kawasaki disease across populations: decoding the role of T and B-cells.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD) is a leading cause of acquired coronary vasculitis in children and remains a critical diagnostic challenge among febrile pediatric patients. To support frontline pediatricians with a more objective diagnostic tool, we developed and implemented KDpredictor, a machine learning-based model for KD risk identification. KDpredictor leverages only the routine blood test features, including complete blood count with differential count, C-reactive protein, and alanine aminotransferase. It also takes the lead in using age-calibrated eosinophil, platelet, and hemoglobin results. Trained using the light gradient boosting machine algorithm on clinical data from 1,927 KD cases and 45,274 febrile controls, KDpredictor achieved strong performance metrics (auROC: 95.7%, auPRC: 72.4%, recall: 0.89) on a reserved test set, outperforming previous models by at least 3% in auROC and 39.3% in auPRC. Additional explainable AI analyses revealed that several top predictive features in KDpredictor are consistent with prior clinical findings. We also evaluated KDpredictor on three independent cohorts collected in East Asia (Taiwan and China) during the COVID-19 period. KDpredictor achieves recall values of 90.9%, 83.7%, and 91.7% on KD samples identified in three independent medical centers, respectively, indicating its applicability across independent clinical settings. In summary, KDpredictor demonstrates robust generalizability in KD risk identification across populations by using only standard blood samples independent of clinical symptoms. KDpredictor is freely available at https://cosbi.ee.ncku.edu.tw/KD_under7/.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.